Eve Initiates Pilot Clinical Study for Libbo ED Film
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Eve Health Group Limited has announced the initiation of a pilot clinical study for Libbo, its oral soluble film for erectile dysfunction treatment. The study aims to compare Libbo's pharmacokinetic profile against a registered reference tablet in healthy male subjects under fasted conditions. Results from this pilot study will inform the design of a subsequent pivotal bioequivalence study necessary for regulatory approval. The company plans to keep shareholders updated on key milestones as the clinical program progresses.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
EVE Health Group Limited on 6ix
Earlier from EVE Health
- Appointment of Chief Executive Officer
- Investor Presentation
- Prospectus
- EVE Placement Update
- EVE Raises $0.9m to Advance Drug Reformulation Strategy
Later from EVE Health
- Quarterly Activities/Appendix 4C Cash Flow Report
- Quarterly Activities/Appendix 4C Cash Flow Report - Amended
- Appendix 4E
- Annual Report to shareholders
- Appendix 4G and Corporate Governance Statement
Follow EVE Health into a list and get an email when it puts out news.
Follow EVE Health